Phase I Safety and Pharmacokinetics Study of Microparticulate Atovaquone (m-Atovaquone; 566C80) in HIV-Infected and Perinatally Exposed Infants and Children

NCT00000773 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

NIH

Sponsor class

Conditions

Pneumonia, Pneumocystis Carinii
HIV Infections

Interventions

DRUG: Atovaquone

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)